Estrogen Receptor - Pipeline Review, H2 2019
Estrogen Receptor - Pipeline Review, H2 2019
SUMMARY
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Estrogen receptor alpha (ERA) is a nuclear receptor that is activated by the sex hormone estrogen. It is encoded by the gene ESR1. It is involved in pathological processes including breast cancer, endometrial cancer, and osteoporosis. It decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displaces RELA/p65 and associated co-regulators from the promoter. It recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP.
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) pipeline Target constitutes close to 27 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 5, 6, 7 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Central Nervous System, Women's Health and Male Health which include indications Breast Cancer, Metastatic Breast Cancer, Osteoporosis, Hormone Sensitive Breast Cancer, Alzheimer's Disease, Bipolar Disorder (Manic Depression), Carcinomas, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Demyelinating Diseases, Ductal Carcinoma In Situ, Endometrial Cancer, Endometriosis, Fallopian Tube Cancer, Hepatocellular Carcinoma, Male Hypogonadism, Melanoma, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Neuromyelitis Optica (Devic’s Syndrome), Non-Small Cell Lung Cancer, Ovarian Cancer, Peritoneal Cancer, Prostate Cancer, Uterine Cancer and Vasomotor Symptoms of Menopause (Hot Flashes).
The latest report Estrogen Receptor - Pipeline Review, H2 2019, outlays comprehensive information on the Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
SUMMARY
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Estrogen receptor alpha (ERA) is a nuclear receptor that is activated by the sex hormone estrogen. It is encoded by the gene ESR1. It is involved in pathological processes including breast cancer, endometrial cancer, and osteoporosis. It decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displaces RELA/p65 and associated co-regulators from the promoter. It recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP.
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) pipeline Target constitutes close to 27 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 5, 6, 7 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Central Nervous System, Women's Health and Male Health which include indications Breast Cancer, Metastatic Breast Cancer, Osteoporosis, Hormone Sensitive Breast Cancer, Alzheimer's Disease, Bipolar Disorder (Manic Depression), Carcinomas, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Demyelinating Diseases, Ductal Carcinoma In Situ, Endometrial Cancer, Endometriosis, Fallopian Tube Cancer, Hepatocellular Carcinoma, Male Hypogonadism, Melanoma, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Neuromyelitis Optica (Devic’s Syndrome), Non-Small Cell Lung Cancer, Ovarian Cancer, Peritoneal Cancer, Prostate Cancer, Uterine Cancer and Vasomotor Symptoms of Menopause (Hot Flashes).
The latest report Estrogen Receptor - Pipeline Review, H2 2019, outlays comprehensive information on the Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1)
- The report reviews Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Overview
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Companies Involved in Therapeutics Development
Amgen Inc
Arvinas Inc
AstraZeneca Plc
Atossa Genetics Inc
Avivia BV
Eagle Pharmaceuticals Inc
Endece LLC
EndoCeutics Inc
Evestra Inc
H3 Biomedicine Inc
Helixmith Co Ltd
Huons Co Ltd
Jina Pharmaceuticals Inc
Novartis AG
Shenogen Pharma Group Ltd
TTC Oncology LLC
Zenopharm LLC
Zentalis Pharmaceuticals LLC
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Drug Profiles
(bazedoxifene acetate + cholecalciferol) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
acolbifene + prasterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARV-471 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dehydrodiconiferyl alcohol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EC-372 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Endoxifen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ERX-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fosfestrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fulvestrant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fulvestrant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fulvestrant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
H-3B5942 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
H-3B6545 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
K-07 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Libidua - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Loseasonique - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDC-1308 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize ESR1 and VEGFR2 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize ER Alpha for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize ER-Alpha for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize ER-Alpha for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Estrogen Receptor Alpha for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNG-1153 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNG-8023 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SR-16234 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TTC-352 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZB-716 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZNc-5 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Dormant Products
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Discontinued Products
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Product Development Milestones
Featured News & Press Releases
Dec 09, 2019: Eagle Pharmaceuticals commences dosing in pilot study for novel estrogen receptor antagonist product candidate
Oct 24, 2019: Arvinas reports initial Phase I data for two cancer assets
Oct 17, 2019: Arvinas to present initial data from ARV-471 at the 2nd Targeted Protein Degradation Summit
Oct 16, 2019: Atossa Genetics receives IRB approval for phase 2 breast cancer study using intraductal technology
Aug 27, 2019: Arvinas announces the initiation of patient dosing in a first-in-human phase 1 study of ARV-471, an estrogen receptor-targeting PROTAC protein degrader
Aug 05, 2019: Eagle Pharmaceuticals announces Clinical Development Plan of innovative product intended to deliver maximum Estrogen Receptor inhibition in patients with Estrogen Receptor (ER)-Positive Breast Cancer
Jun 25, 2019: Arvinas receives authorization to proceed for ARV-471, a PROTAC Protein Degrader to treat patients with Locally Advanced or Metastatic ER+ / HER2- Breast Cancer
May 16, 2019: Eisai Presents data on H3B-6545 at 55th ASCO Annual Meeting
Mar 27, 2019: Combo better for HR+ breast cancer patients
Dec 07, 2018: Arvinas presents preclinical data on protein degrader, ARV-471, at the 2018 San Antonio Breast Cancer Symposium (SABCS)
Oct 30, 2018: Eagle Pharmaceuticals announces results of study for fulvestrant
Oct 20, 2018: New option for women with advanced breast cancer resistant to hormone therapy
Jul 10, 2018: Cancer Discovery Features H3 Biomedicine Paper Highlighting Effects of Selective Estrogen Receptor Covalent Antagonists (SERCAs) in ERa Wild-Type and Mutant Breast Cancer Models
Jun 01, 2018: ENDECE Attending 2018 Bio International in Boston
Mar 26, 2018: Mayne Pharma Launches Generic Quartette in the U.S., Another Womens Health Product
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Overview
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Companies Involved in Therapeutics Development
Amgen Inc
Arvinas Inc
AstraZeneca Plc
Atossa Genetics Inc
Avivia BV
Eagle Pharmaceuticals Inc
Endece LLC
EndoCeutics Inc
Evestra Inc
H3 Biomedicine Inc
Helixmith Co Ltd
Huons Co Ltd
Jina Pharmaceuticals Inc
Novartis AG
Shenogen Pharma Group Ltd
TTC Oncology LLC
Zenopharm LLC
Zentalis Pharmaceuticals LLC
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Drug Profiles
(bazedoxifene acetate + cholecalciferol) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
acolbifene + prasterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARV-471 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dehydrodiconiferyl alcohol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EC-372 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Endoxifen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ERX-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fosfestrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fulvestrant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fulvestrant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fulvestrant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
H-3B5942 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
H-3B6545 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
K-07 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Libidua - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Loseasonique - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDC-1308 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize ESR1 and VEGFR2 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize ER Alpha for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize ER-Alpha for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize ER-Alpha for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Estrogen Receptor Alpha for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNG-1153 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNG-8023 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SR-16234 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TTC-352 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZB-716 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZNc-5 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Dormant Products
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Discontinued Products
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Product Development Milestones
Featured News & Press Releases
Dec 09, 2019: Eagle Pharmaceuticals commences dosing in pilot study for novel estrogen receptor antagonist product candidate
Oct 24, 2019: Arvinas reports initial Phase I data for two cancer assets
Oct 17, 2019: Arvinas to present initial data from ARV-471 at the 2nd Targeted Protein Degradation Summit
Oct 16, 2019: Atossa Genetics receives IRB approval for phase 2 breast cancer study using intraductal technology
Aug 27, 2019: Arvinas announces the initiation of patient dosing in a first-in-human phase 1 study of ARV-471, an estrogen receptor-targeting PROTAC protein degrader
Aug 05, 2019: Eagle Pharmaceuticals announces Clinical Development Plan of innovative product intended to deliver maximum Estrogen Receptor inhibition in patients with Estrogen Receptor (ER)-Positive Breast Cancer
Jun 25, 2019: Arvinas receives authorization to proceed for ARV-471, a PROTAC Protein Degrader to treat patients with Locally Advanced or Metastatic ER+ / HER2- Breast Cancer
May 16, 2019: Eisai Presents data on H3B-6545 at 55th ASCO Annual Meeting
Mar 27, 2019: Combo better for HR+ breast cancer patients
Dec 07, 2018: Arvinas presents preclinical data on protein degrader, ARV-471, at the 2018 San Antonio Breast Cancer Symposium (SABCS)
Oct 30, 2018: Eagle Pharmaceuticals announces results of study for fulvestrant
Oct 20, 2018: New option for women with advanced breast cancer resistant to hormone therapy
Jul 10, 2018: Cancer Discovery Features H3 Biomedicine Paper Highlighting Effects of Selective Estrogen Receptor Covalent Antagonists (SERCAs) in ERa Wild-Type and Mutant Breast Cancer Models
Jun 01, 2018: ENDECE Attending 2018 Bio International in Boston
Mar 26, 2018: Mayne Pharma Launches Generic Quartette in the U.S., Another Womens Health Product
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Amgen Inc, H2 2019
Pipeline by Arvinas Inc, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Atossa Genetics Inc, H2 2019
Pipeline by Avivia BV, H2 2019
Pipeline by Eagle Pharmaceuticals Inc, H2 2019
Pipeline by Endece LLC, H2 2019
Pipeline by EndoCeutics Inc, H2 2019
Pipeline by Evestra Inc, H2 2019
Pipeline by H3 Biomedicine Inc, H2 2019
Pipeline by Helixmith Co Ltd, H2 2019
Pipeline by Huons Co Ltd, H2 2019
Pipeline by Jina Pharmaceuticals Inc, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Shenogen Pharma Group Ltd, H2 2019
Pipeline by TTC Oncology LLC, H2 2019
Pipeline by Zenopharm LLC, H2 2019
Pipeline by Zentalis Pharmaceuticals LLC, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Amgen Inc, H2 2019
Pipeline by Arvinas Inc, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Atossa Genetics Inc, H2 2019
Pipeline by Avivia BV, H2 2019
Pipeline by Eagle Pharmaceuticals Inc, H2 2019
Pipeline by Endece LLC, H2 2019
Pipeline by EndoCeutics Inc, H2 2019
Pipeline by Evestra Inc, H2 2019
Pipeline by H3 Biomedicine Inc, H2 2019
Pipeline by Helixmith Co Ltd, H2 2019
Pipeline by Huons Co Ltd, H2 2019
Pipeline by Jina Pharmaceuticals Inc, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Shenogen Pharma Group Ltd, H2 2019
Pipeline by TTC Oncology LLC, H2 2019
Pipeline by Zenopharm LLC, H2 2019
Pipeline by Zentalis Pharmaceuticals LLC, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Amgen Inc
Arvinas Inc
AstraZeneca Plc
Atossa Genetics Inc
Avivia BV
Eagle Pharmaceuticals Inc
Endece LLC
EndoCeutics Inc
Evestra Inc
H3 Biomedicine Inc
Helixmith Co Ltd
Huons Co Ltd
Jina Pharmaceuticals Inc
Novartis AG
Shenogen Pharma Group Ltd
TTC Oncology LLC
Zenopharm LLC
Zentalis Pharmaceuticals LLC
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Amgen Inc
Arvinas Inc
AstraZeneca Plc
Atossa Genetics Inc
Avivia BV
Eagle Pharmaceuticals Inc
Endece LLC
EndoCeutics Inc
Evestra Inc
H3 Biomedicine Inc
Helixmith Co Ltd
Huons Co Ltd
Jina Pharmaceuticals Inc
Novartis AG
Shenogen Pharma Group Ltd
TTC Oncology LLC
Zenopharm LLC
Zentalis Pharmaceuticals LLC
